Abstract: Glioblastoma (GBM) originates from glial cells, and complete surgical resection followed by radiotherapy and chemotherapy is the current standard treatment. However, gliomas are subjected to not only accelerated cell death after radiotherapy and chemotherapy but also cellular senescence. Senescent cells produce a senescence-associated secretory phenotype (SASP), which has a dual effect on the tumor microenvironment. The "one-two punch" strategy of specifically eliminating senescent cells and inhibiting SASP-derived secretions provides a new direction for tumor therapy. In this article, we review the mechanisms that mediate tumor cellular senescence and SASP, the elimination of senescent cells by senolytics for SASP inhibition, and the current situation of the "one-two punch" strategy for the treatment of glioma.